The effect of anti-seizure medications on Alzheimer's disease (AD) risk and AD-related symptoms: A scoping review
Authors:
- Jonathan P WilliamsJWJonathan P Williams
- Yiqi ZhuYZYiqi Zhu
- Ramkrishna K SinghRSRamkrishna K Singh
- Rohan RaniRRRohan Rani
- Katherine McGuireKMKatherine McGuire
- Ramana KoladyRKRamana Kolady
- Kim LipseyKLKim Lipsey
- Sridharan Gopalsamy RamaswamySRSridharan Gopalsamy Ramaswamy
- Vishnuvardhan ThotakuraVTVishnuvardhan Thotakura
- 21 March 2025
- journal article
- review article
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 3-14
Abstract
Background: As the fastest-growing segment of the population, adults over 65 are at the most significant risk for Alzheimer's disease (AD). Older adults often use anti-seizure medications (ASMs), which can negatively impact cognitive function, mood, and behavior, mimicking AD or its symptoms. Understanding the effects of ASMs across diverse older adults is crucial, given that some ethnoracial groups are at higher risk for AD or more severe symptoms compared to non-Hispanic Whites. Objective: To summarize the current evidence on the association of ASMs with AD risk and AD-related symptoms and explore the inclusion of ethnoracial minority groups in these studies. Methods: Data sources included PubMed/MEDLINE, EMBASE, and SCOPUS for English-language studies published between 1990–2024. Selected studies were peer-reviewed, cross-sectional, longitudinal, case-control, and clinical trials on AD dementia or related symptoms and ASMs. Study quality was rated by the Oxford Centre for Evidence-Based Research Medicine. Results: A total of 27 studies with 1,241,796 participants were included. Data on AD risk from level IB-IIIB evidence studies showed mixed results, with some indicating an increased association with ASM use [OR = 1.05–1.16, 95% CI: 1.01–1.24]. Studies on AD-related symptoms from level IB-IV evidence also showed mixed results. Only three North American studies explicitly included race/ethnicity; most were conducted in European countries. Conclusions: ASM use may be modestly associated with an increased risk of AD among the older adult population, but current data are inconclusive. The association of ASMs on AD-related symptoms varied. Future studies should emphasize reporting sociodemographic data and include diverse cohorts to enhance the applicability of findings.Keywords
Funding Information
- National Institute on Aging (R01AG068183)
- National Institute on Aging (R01AG074302)
- National Institute on Aging (R01AG067428)
This publication has 49 references indexed in Scilit:
- Pharmacological aspects of antiseizure medications: From basic mechanisms to clinical considerations of drug interactions and use of therapeutic drug monitoringEpileptic Disorders, 2023
- Association of Dementia Risk With Focal Epilepsy and Modifiable Cardiovascular Risk FactorsJAMA Neurology, 2023
- 2023 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2023
- Antiseizure Medications for Adults With EpilepsyJAMA, 2022
- Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentationAlzheimer's & Dementia, 2021
- Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform ActivityJAMA Neurology, 2021
- Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020–2060)Alzheimer's & Dementia, 2021
- Benzodiazepines and antidepressants: Effects on cognitive and functional decline in Alzheimer's disease and Lewy body dementiaInternational Journal of Geriatric Psychiatry, 2020
- Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer DiseaseArchives of General Psychiatry, 2011
- Antiepileptic drug use in nursing home admissionsAnnals of Neurology, 2003